ALNYLAM PHARMACEUTICALS INC (ALNY) Forecast, Price Target & Analyst Ratings

NASDAQ:ALNY • US02043Q1076

Current stock price

339.41 USD
+6.41 (+1.92%)
At close:
338.94 USD
-0.47 (-0.14%)
Pre-Market:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALNYLAM PHARMACEUTICALS INC (ALNY).

Forecast Snapshot

Consensus Price Target

Price Target
$454.89
+ 34.02% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Apr 30, 2026
Period
Q1 / 2026
EPS Estimate
$1.01
Revenue Estimate
1.145B
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
78.89%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$454.89
Upside
+ 34.02%
From current price of $339.41 to mean target of $454.89, Based on 36 analyst forecasts
Low
$238.36
Median
$460.02
High
$594.30

Price Target Revisions

1 Month
-1.57%
3 Months
-8.36%

Price Target Summary

36 Wall Street analysts provided a forecast for the next 12 months for ALNY. The average price target is 454.89 USD. This implies a price increase of 34.02% is expected in the next year compared to the current price of 339.41.
The average price target has been revised downward by 8.36% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

ALNY Current Analyst RatingALNY Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 5 10 15

Analyst Ratings History

ALNY Historical Analyst RatingsALNY Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 0 0 0 0 0

Analyst Ratings Consensus

ChartMill Buy Consensus
78.89%
ALNY was analyzed by 36 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about ALNY.
In the previous month the buy percentage consensus was at a similar level.
ALNY was analyzed by 36 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-13Truist SecuritiesMaintains Buy -> Buy
2026-03-25Chardan CapitalMaintains Buy -> Buy
2026-03-25HC Wainwright & Co.Reiterate Buy -> Buy
2026-03-16JefferiesDowngrade Buy -> Hold
2026-02-18HC Wainwright & Co.Reiterate Buy -> Buy
2026-02-17Freedom Capital MarketsUpgrade Hold -> Buy
2026-02-17Canaccord GenuityMaintains Buy -> Buy
2026-02-13Chardan CapitalMaintains Buy -> Buy
2026-02-12NeedhamMaintains Buy -> Buy
2026-01-30B of A SecuritiesMaintains Buy -> Buy
2026-01-30Morgan StanleyMaintains Equal-Weight -> Equal-Weight
2026-01-30HC Wainwright & Co.Maintains Buy -> Buy
2026-01-28BarclaysInitiate Overweight
2026-01-20RBC CapitalMaintains Outperform -> Outperform
2026-01-20Wells FargoMaintains Equal-Weight -> Equal-Weight
2026-01-12NeedhamMaintains Buy -> Buy
2026-01-12B of A SecuritiesMaintains Buy -> Buy
2026-01-08Truist SecuritiesMaintains Buy -> Buy
2025-12-15Leerink PartnersMaintains Market Perform -> Market Perform
2025-12-11StifelMaintains Buy -> Buy
2025-11-11Wells FargoMaintains Equal-Weight -> Equal-Weight
2025-10-31BarclaysMaintains Overweight -> Overweight
2025-10-31Piper SandlerReiterate Overweight -> Overweight
2025-10-30JefferiesMaintains Buy -> Buy
2025-10-17Truist SecuritiesMaintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Apr 30, 2026
Period
Q1 / 2026
EPS Estimate
$1.01
Revenue Estimate
1.145B
Revenue Q2Q
92.70%
EPS Q2Q
330.04%
Number of Analysts
24

Next Earnings Revisions

Revenue (1 Month)
0.09%
Revenue (3 Months)
-6.15%
EPS (1 Month)
-1.93%
EPS (3 Months)
-25.29%

Next Earnings Summary

ALNY is expected to report earnings on 4/30/2026. The consensus EPS estimate for the next earnings is 1.01 USD and the consensus revenue estimate is 1.15B USD.
The next earnings revenue estimate has been revised downward by 6.15% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
ALNY revenue by date.ALNY revenue by date.
1.828B
76.24%		2.248B
22.97%		3.714B
65.19%		5.682B
52.99%		7.487B
31.77%		8.919B
19.13%		10.07B
12.91%		11.504B
14.24%		12.633B
9.81%		13.158B
4.16%		14.044B
6.73%
EBITDA
YoY % growth
ALNY ebitda by date.ALNY ebitda by date.
-228.121M
69.20%		-120.215M
47.30%		557.236M
563.53%		1.305B
134.19%		2.152B
64.90%		2.383B
10.73%		3.24B
35.96%		3.953B
22.01%		5.011B
26.76%		3.927B
-21.63%		N/A
EBIT
YoY % growth
ALNY ebit by date.ALNY ebit by date.
-282.175M
64.06%		-176.885M
37.31%		501.578M
383.56%		1.054B
110.14%		1.772B
68.12%		2.407B
35.84%		2.828B
17.49%		3.504B
23.90%		4.602B
31.34%		5.505B
19.62%		6.089B
10.61%
Operating Margin
ALNY operating margin by date.ALNY operating margin by date.
-15.43%-7.87%13.51%18.55%23.67%26.99%28.08%30.46%36.43%41.84%43.36%
EPS
YoY % growth
ALNY eps by date.ALNY eps by date.
-3.56
58.89%		-2.17
39.04%		1.98
191.24%		6.83
244.73%		10.75
57.53%		13.49
25.50%		20.71
53.49%		24.09
16.29%		29.83
23.85%		33.71
12.99%		38.79
15.06%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		1.01
330.04%		1.46
387.11%		1.89
-10.52%		2.44
197.00%		2.88
184.17%		2.92
99.23%		3.28
73.77%		3.52
44.63%
Revenue
Q2Q % growth		1.145B
92.70%		1.349B
74.36%		1.505B
20.49%		1.687B
53.78%		1.881B
64.28%		1.995B
47.89%		2.112B
40.33%		2.244B
33.02%
EBITDA
Q2Q % growth		172.98M
432.54%		253.09M
1,983.05%		351.95M
-14.19%		390.35M
108.32%		N/AN/AN/AN/A
EBIT
Q2Q % growth		176.08M
874.06%		236.43M
1,559.53%		321.27M
-12.69%		394.5M
199.50%		441.1M
150.51%		445.9M
88.60%		485.92M
51.25%		532.76M
35.05%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

ALNY Yearly Revenue VS EstimatesALNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
ALNY Yearly EPS VS EstimatesALNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
89.60%
EPS Next 5 Year
64.83%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
32.54%
Revenue Next 5 Year
24.60%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
60.40%
EBIT Next 5 Year
46.92%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ALNYLAM PHARMACEUTICALS INC / ALNY Forecast FAQ

Can you provide the average price target for ALNYLAM PHARMACEUTICALS INC stock?

36 analysts have analysed ALNY and the average price target is 454.89 USD. This implies a price increase of 34.02% is expected in the next year compared to the current price of 339.41.

What is the next earnings date for ALNY stock?

ALNYLAM PHARMACEUTICALS INC (ALNY) will report earnings on 2026-04-30.

Can you provide the consensus estimates for ALNYLAM PHARMACEUTICALS INC next earnings?

The consensus EPS estimate for the next earnings of ALNYLAM PHARMACEUTICALS INC (ALNY) is 1.01 USD and the consensus revenue estimate is 1.15B USD.

How many analysts cover ALNYLAM PHARMACEUTICALS INC (ALNY) stock?

The number of analysts covering ALNYLAM PHARMACEUTICALS INC (ALNY) is 36.